Concepedia

Author

Jack Ansell

Boston UniversityORCID

Also Known As

Ansell, Jack., Bengt Eriksson, J Ansell, J E Ansell, J. ANSELL, J. Ansell, J. E. Ansell, J.E. Ansell, JACK ANSELL, JACK E. ANSELL

334

Publications

32.7K

Citations

71

H-Index

108

Concepts

All Affiliations

Boston UniversityClinical Research InstituteLenox Hill HospitalDuke Medical CenterStanford University
JA

About

Jack Ansell is an author at Boston University specializing in medicine, thrombosis, and cardiovascular disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

39

59

8.9K

2

Public Health

15

17

1.7K

3

Health Sciences

7

7

474

4

Engineering

3

3

49

5

Nursing

1

1

40

Jack Ansell

×

114

Publications

23.6K

Citations

57

H-Index

YearCitations

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Christopher B. Granger, John H. Alexander, John J.V. McMurray,

New England Journal of Medicine

2011

8.8K

Pharmacology and Management of the Vitamin K Antagonists

Jack Ansell, Jack Hirsh, Elaine M. Hylek,

CHEST Journal

2008

2.1K

The Pharmacology and Management of the Vitamin K Antagonists

Jack Ansell, Jack Hirsh, L. Poller,

CHEST Journal

2004

1.5K

The Perioperative Management of Antithrombotic Therapy

James D. Douketis, Peter B. Berger, Andrew Dunn,

CHEST Journal

2008

834

American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy

Daniel M. Witt, Robby Nieuwlaat, Nathan P. Clark,

Blood Advances

2018

489

Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes

Benjamin A. Steinberg, Peter Shrader, Laine Thomas,

Journal of the American College of Cardiology

2016

481

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

Renato D. Lópes, John H. Alexander, Sana M. Al‐Khatib,

American Heart Journal

2010

455

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation

Emily C. O’Brien, DaJuanicia N. Simon, Laine Thomas,

European Heart Journal

2015

436

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement

Michael R. Lassen, Bruce L. Davidson, Alexander Gallus,

Journal of Thrombosis and Haemostasis

2007

370

American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

Jack Hirsh, Valentı́n Fuster, Jack Ansell,

Journal of the American College of Cardiology

2003

302

Page 1